TG01 Vaccine
Phase 2Vaccine
TG01 Vaccine is one of 40 biologic programs targeting Pancreatic Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
307 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
TG01 Vaccine
UUniversity of Kansas Medical Center
Phase 2
Secretin-Ferring
FerringPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TG01 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details